RGB-5088
/ Hangzhou Reprogenix Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 01, 2026
A Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=10 | Not yet recruiting | Sponsor: Hangzhou Reprogenix Bioscience, Inc
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
September 16, 2025
Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: Hangzhou Reprogenix Bioscience, Inc | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
December 12, 2024
Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients with Type 1 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=10 | Not yet recruiting | Sponsor: Hangzhou Reprogenix Bioscience, Inc
New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
1 to 3
Of
3
Go to page
1